S&D Co (260970) Q1 2026 earnings summary

Executive summary

• Specializes in functional food ingredients and health supplements, with a focus on natural and bio-based products for food and health industries.

• Listed on KOSDAQ since 2021, with a stable shareholder structure and no recent changes in major shareholders.

• Recognized for R&D and innovation, holding 26 active patents and multiple industry certifications.

Financial highlights

• Q1 2026 revenue: KRW 45.47 billion, up from KRW 35.71 billion in Q1 2025.

• Q1 2026 net income: KRW 6.38 billion, up from KRW 4.39 billion in Q1 2025.

• Operating income for Q1 2026: KRW 8.13 billion, up from KRW 2.37 billion in Q1 2025.

• Basic EPS for Q1 2026: KRW 2,204, up from KRW 1,518 in Q1 2025.

• Cash and cash equivalents at Q1 2026: KRW 39.72 billion, up from KRW 26.55 billion at year-end 2025.

Outlook and guidance

• Plans to diversify business through new ventures, with recent additions to business objectives for future growth.

• Continued focus on R&D, especially in functional and health food ingredients, with new product approvals and ongoing clinical trials.

• Intends to maintain stable dividends and enhance shareholder value.